Literature DB >> 9370182

Impact of nitric oxide on blood pressure in hemodialysis patients.

F Madore1, L Prud'homme, J S Austin, G Blaise, M Francoeur, M Léveillé, M Prud'homme, P Vinay.   

Abstract

Nitric oxide (NO) is a powerful vasoactive agent that contributes to the regulation of blood pressure (BP). However, the role of NO in uremic patients and during the course of hemodialysis is still debated. Blood L-arginine concentrations and exhaled NO concentrations were measured in 22 healthy controls and in 22 hemodialysis patients before and after dialysis. On the basis of their BP response during hemodialysis, the patients were divided into three groups: 6 of the 22 patients presented with a decrease in BP during dialysis (group 1), eight presented with a stable BP (group 2), and eight with an increase in BP (group 3). The exhaled NO concentration was higher in dialysis patients than in healthy controls (22.7 +/- 2.6 ppb in dialysis patients v 16.7 +/- 0.9 ppb in controls, mean +/- SEM, P = 0.044). The predialysis and postdialysis exhaled NO concentrations were inversely correlated with the change in BP during hemodialysis (r = -0.47, P = 0.013). Patients with a decrease in BP (group 1) had the highest NO concentrations; patients with an increase in BP (group 3) had the lowest values; and patients with a stable BP during the course of dialysis (group 2) had intermediary values (trend test, P = 0.0291). In addition, both the exhaled NO concentration and the blood L-arginine concentration decreased during dialysis in all patients (P = 0.005 and P = 0.001, respectively). These results provide several novel insights into NO metabolism and BP regulation during hemodialysis: (1) maintenance hemodialysis is associated with a chronic increase in NO concentrations; (2) changes in BP during hemodialysis are inversely correlated with exhaled NO concentrations, higher NO levels being associated with a decrease in BP and lower NO levels with an increase in BP during dialysis; (3) blood L-arginine levels decrease during hemodialysis, and this reduction may in turn influence NO production.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9370182     DOI: 10.1016/s0272-6386(97)90491-1

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  6 in total

Review 1.  [Thrombocytopathy and blood complications in uremia].

Authors:  Walter H Hörl
Journal:  Wien Klin Wochenschr       Date:  2006-04       Impact factor: 1.704

2.  Indices of activity of the nitric oxide system in hemodialysis patients.

Authors:  R J Schmidt; J Domico; L S Samsell; S Yokota; T S Tracy; M I Sorkin; K Engels; C Baylis
Journal:  Am J Kidney Dis       Date:  1999-08       Impact factor: 8.860

Review 3.  Management of hypertension in hemodialysis patients.

Authors:  C Venkata S Ram; Andrew Z Fenves
Journal:  Curr Hypertens Rep       Date:  2009-08       Impact factor: 5.369

4.  Malondialdehyde can predict survival in hemodialysis patients.

Authors:  Crina Claudia Rusu; Simona Racasan; Ina Maria Kacso; Diana Moldovan; Alina Potra; Ioan Mihai Patiu; Dan Vladutiu; Mirela Gherman Caprioara
Journal:  Clujul Med       Date:  2016-04-15

5.  Is There a Correlation between Vitamin C Status and Catecholamines Concentrations in Hemodialysis Patients?

Authors:  Isaline Coquet; Jean-Marc Doise; Jean-Claude Guilland; Catherine Vergely; Christiane Mousson; Luc Rochette
Journal:  Int J Biomed Sci       Date:  2008-06

6.  Alterations in conformational state of albumin in plasma in chronic hemodialyzed patients.

Authors:  Anna Pieniazek; Lukasz Gwozdzinski; Zbigniew Zbrog; Krzysztof Gwozdzinski
Journal:  PLoS One       Date:  2018-03-19       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.